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Microfluidic models of the gastrointestinal (GI) tract, known as gut-on-a-chip 
devices, mimic the structural, absorptive, pathophysiological and microbial environment 
of the human gut. They have potential to revolutionize drug delivery testing and replace 
animal testing to improve efficacy. However, current models lack methods for quantitative 
assessment of molecular cues that determine biological function, limiting their ability to 
discern the efficacy of treatments on diseases. Team BioCHIPS developed a 
polydimethylsiloxane (PDMS) gut-on-a-chip model lined with Caco-2 intestinal epithelial 
cells, with the novel incorporation of catechol-chitosan biomolecular sensors. This is the 
first instance of in situ assembled biomolecular sensors that provide direct electrical 
connectivity and assessment of glucose level in real time. These sensors enable quantifying 
changes in the physiological conditions due to alterations in glucose concentration, to 
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Chapter 1: Introduction 
According to the National Center for Advancing Translational Sciences (NCATS), 
more than 30 percent of promising medications have failed in human clinical trials, despite 
positive results from animal trials.1 It is difficult to determine whether a medication is safe 
for humans through animal testing and is even more difficult to obtain approval for the 
distribution of the medication.2 The United States Food and Drug Administration (FDA) 
estimates that it takes about ten months for a ‘Standard Review’ of new drugs that offer 
minor improvements for existing therapies and six months for ‘Priority Review’ drugs that 
are major advances in both existing and non-existing treatments.3 While the timeline 
proposed by the FDA is ideal in principle, the process can extend to over five years and is 
followed by four phases of clinical trials, which can add several years to the timeline.3 The 
process to research and develop a typical drug takes, on average, 7.3 years and $650 
million.4 The resulting process of research and development is not only time consuming, 
but also expensive.4 These factors severely limit the development and availability of new 
drugs, particularly those that might have limited markets. 
In vivo and in vitro laboratory techniques are the most commonly used platforms 
for disease modeling and drug and chemical testing.5 Although they have been able to 
provide information about the effects of the drug in physiological conditions, they present 
several drawbacks. In vivo models can produce integrated multi-organ responses to 
experimental substances; however, multi-organ systems that may seem advantageous 
create difficulties when trying to pinpoint specific physiological and pathological 
responses to a particular cell group.5 In addition, applying animal model data to human 
conditions are limited because animals have different physiological responses and 
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anatomical features compared to humans.6 These differences can lead to the failure to 
adequately mimic clinical diseases or cause publication bias, where the publication of 
results depends on the hypothesis being tested, and the significance of the results depends 
on the quality of the research.7 On the other hand, in vitro platforms are useful for studying 
the molecular basis of physiological and pathological responses, such as identifying the 
proteins, genes, and other components involved, but they can fail to simulate complex cell-
cell and cell-cell matrix interactions.8 
The limitations of the traditional models have led to the failure of a number of new 
drug candidates throughout various testing phases due to unexpected side effects or low 
efficiency.9 To overcome these limitations, scientists are looking into a new way to test 
drugs and model diseases: organ-on-a-chip models (OoC). OoC models are microchips 
created by coating glass slides with human cells to imitate a specific organ.10 Current 
research of OoC models focus on modeling the structure and function of human organs and 
systems on a microfluidic device, creating a “newer human cell based approach.”1 With 
this approach, pharmaceuticals can be efficiently tested without animal or human test 
subjects. The chip would allow for a faster drug screening process, which will ultimately 
benefit pharmaceutical and biomedical research companies as well as the public.  
This research focuses on the gastrointestinal tract to create a gut-on-a-chip model 
integrated with sensors. The sensors will provide a more quantitative analysis by measuring 
the quantitative effect of a potential treatment on a disease. If sensors can be successfully 
integrated into the gut-on-a-chip model, then treatments can be more accurately tested and 




Chapter 2: Literature Review 
2.1 Gut-on-a-Chip 
2.1.1 The Gastrointestinal Tract 
 
Figure 2.1 (A) Depiction of the parts of the gastrointestinal tract11  (B) Depiction of the parts of 
the small intestine12 
 
The gastrointestinal (GI) tract (Figure 2.1A) is an organ system in the body 
composed of the stomach, small intestine, and large intestine.13 This research will focus on 
both the small and large intestines, commonly known as the gut. 
The small intestine is about 6 m long and very tightly folded (Figure 2.1B).14  It is 
a long, tube-like structure made up of three segments: duodenum, jejunum, and ileum.15 
These sections carry semi-digested food from the stomach through a process of further 
digestion where nutrients are absorbed while the leftover waste travels to the large 
intestine. The small intestine most notably contains numerous villi, which are 
approximately 500 μm in length, as well as tight-junctions between the cells.16 The villi 
are hair-like structures that increase the inner surface area, which, in combination with the 





Figure 2.2 Depiction of the parts of the large intestine17 
 
The large intestine, also known as the colon, is only 1.5 m long, but slightly wider 
in diameter than the small intestine, which is why it is known as the larger one of the 
intestines (Figure 2.2).18 The colon is also made up of three segments: ascending, 
transverse and descending.17  When the digested food passes through the small intestine, it 
empties out into the large intestine. The colon reabsorbs water and pushes the food waste 
towards the rectum. The rectum collects leftover waste until it is emptied through the 
anus.13 
  One of the most important characteristics of the intestinal system is its microbiome 
and its associated microbiota. The intestinal microbiome refers to the collection of 
microorganisms that occupy a specific environment, while the microbiota is in reference 
to the actual microorganisms.17 The environment of the intestine has a dynamic pH 
depending on location. As a result, the species of bacteria differ based on the local 
conditions. Both play an important role in the development and function of the 
gastrointestinal structure.17 The microbiome contains both beneficial and detrimental kinds 
of bacteria.17 The beneficial bacteria, such as Lactobacillus, are ingested and aid in the 
human digestive process.17 Detrimental bacteria, such as Clostridium difficile and certain 
strains of Escherichia coli, are also essential for digestive processes, but can cause harmful 
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diseases if humans are exposed to them from external sources in large amounts.17 Both 
types of bacteria are vital to the function of the human gut. According to a study conducted 
by Abrams, Bauer, and Sprinz, rats grown in germ-free conditions exhibited reduced 
intestinal surface area and decreased epithelial cell turnover.19 These morphological 
differences lead to a less effective intestinal system and GI functional disorders.20 
Nevertheless, in the case of overgrowth, bacteria can produce toxins and increase the 
permeability of the gut membrane, also resulting in harmful diseases. 
2.1.2 Applicability to OoC Model 
Developing in vitro models of the human gut plays a key role in addressing 
challenges with GI tract diseases, metabolism, transport, and oral absorption of drugs and 
nutrients. These cell culture models contain a transepithelial barrier that can study the fluid 
and transport properties of cells.21 Current in vivo methods for toxicity evaluation of drugs 
are impractical for the GI tract due to the large experimental scale and the immunological 
differences between species used in animal studies and human cell culture.22 These 
obstacles need to be overcome because the gut is one of the most important organ systems, 
as it contains major mechanisms for the digestion and absorption of nutrients needed for 
bodily functions. In addition, the gut can be targeted for drug delivery since it contains its 
own microbiome, which controls important processes that maintain the immune system. 
On the other hand, the gut is difficult to replicate due to the harsh acidic environment and 
varying pH ranges from the proximal end of the colon to the cecum, the junction of the 
small and large intestine.23 The thin mucous layer adds complexity due to its μm size. 
Furthermore, the tight junctions prevent highly charged and large molecules from entering 
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the GI tract. Thus, conducting research on the GI tract and its diseases presents its own 
unique set of obstacles.  
Despite these limitations, the gut was chosen for this OoC model because it has its 
own microbiome, which makes it independent. Compared to an organ that is completely 
integrated into the human body and whose functions depend on other organs, the isolation 
of the gut provides an optimal testing area. The human gut-on-a-chip model is able to 
accurately present the three-dimensional (3D) structures, differentiated cell types, and 
physiological functions of the GI tract, thereby providing an alternative in vitro model to 
study intestinal diseases and drug development.24 This model can simulate fluid flow, 
mechanical stress, epithelial cell behavior, and transfection potential of the gut to monitor 
nanoparticle transport and drug delivery in real time using imaging techniques such as 
confocal microscopy and flow cytometry. Different concentrations and conditions can be 
researched and trialed to rapidly test the drug delivery system. Moreover, 3D cell cultures 
are more advantageous than two-dimensional (2D) cell cultures. A study done by Carrel et 
al. concluded that cells that were three-dimensionally cultured had a longer life span.25 In 
order to ensure that life span, a constant supply of nutrients to the cells and the removal of 
metabolites are needed to allow the 3D structure to grow properly.26 
2.1.3 Gut-on-a-Chip Characteristics 
 




Yu et al. developed a microfluidic device that has a single layer of human intestinal 
epithelial cells that grow on a flexible, porous membrane inside the central chamber, 
recreating the intestinal barrier.27 This device (Figure 2.3) exhibits a cyclic mechanical 
deformation that mimics the peristaltic, or wave-like, motions that move along the 
digestive tract. An important characteristic of this gut-on-a-chip model is the intestinal 
tissue-tissue interface, which allows fluids to flow through the cell layer. Additionally, this 
model is able to grow and sustain common intestinal microbes on the surface of the cultured 
intestinal cells. Gut-on-a-chip models successfully simulate the physiological properties 
that are important in understanding intestinal diseases and drug testing.24  
  
Figure 2.4 A) Schematic depiction of fully packaged microfluidic culture system. B) Photograph 
of a packaged microchip. C) Human mesenchymal vessels for dynamic mechanical stimulation of 
mesenchymal cells cultured on two microfluidic vessels. (Scale bar = 200 μm)28 
 
Another important aspect of OoC models is the microfluidic system that acts as a 
pathway for miniscule amounts of liquids (Figure 2.4). Microfluidic systems simulate 
blood vessels, a network of tubes that allows blood to circulate within the body. When 
drugs are ingested, internal organs absorb and transport them throughout the body via blood 
vessels. Due to the crucial role blood vessels play in drug delivery, microfluidic systems 
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are imperative to developing a viable OoC. A key principle of the microfluidic system is 
fluidic shear stress, which is when fluid particles move relative to one another at different 
velocities. Concepts such as peristaltic movement, chemical gradients, and cell-cell 
communication are also integrated into the final design of the model. Researchers are able 
to conduct parametric studies when these factors are monitored and managed. 
2.1.4 Current Research on Gut-on-a-Chip 
The current model, with its similarities to the human gut allows researchers to test 
novel drug delivery techniques. Drug delivery techniques have evolved from drug-loaded 
nanoscale liposomes to polymeric nanoparticles that can be chemically modified for in vivo 
stability to target a disease.21 Vacuum channels, pressurized to mimic peristalsis, are 
combined with the diverse microenvironment, which uses epithelial cells on hydrogel 
substrates to replicate the lining of the GI tract and test the development of intestinal 
disorders.20 Using this model, further studies could be done on metabolism, absorption of 
drugs and chemicals, and an assortment of diseases.  
With this model, Gamboa and Leong were able to test a nanoparticle-mediated 
delivery system that can minimize the degradation of the cargo, extend the retention time 
in the gut, and enhance transport to the systemic circulation. Yu et al. improved the model 
by designing a 3D villous model that showed how villous scaffolds facilitate cell 
differentiation and absorption.27 The villous scaffolds allow for transport away from cells 
in a basolateral direction, while hard surfaces do not permit transport through the cell 
monolayer.29 Costello et. al. found that in the gut-on-a-chip model with liquid sheer, there 
was also increased cell proliferation and more active (as opposed to passive) glucose 
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transport at higher rates under flow.30 This is favorable to the 2D model by creating a more 
accurate representation of the microbiota in the gut.  
Another study used droplet microfluidics, a tool that allows for the use of miniscule 
(pico- to nano-liters) amounts of sample for low cross-contamination and faster mixing.26 
Droplet formation can be controlled by hydrodynamic and electro-hydrodynamic 
properties of a particular channel. These properties relate to the study of uncharged and 
charged fluids in motion, such as flow rate, pressure, density, and temperature. Electro-
hydrodynamics involves integrating electrodes that transmit an electrical signal to control 
the formation of the droplets.26 This study can be combined with the gut-on-a-chip system 




2.2.1 Materials for Fabrication 
As microfluidic devices are becoming powerful tools in the realm of biological, 
chemical, and medical analysis, materials like glass, silicon, plastics, hydrogels, and 
elastomers have been introduced and utilized in biofabrication. Finding and implementing 
the balance between the effectiveness of the material, ease of fabrication, and cost has been 
one of the challenges researchers face in the development of the OoC model.  
Plastics have become a popular option due to their rapid prototyping potentials at a 
low cost and high flexibility to meet the researchers’ needs.31 Thermosets, such as SU-8 
photoresist and polyimide, can withstand high temperatures, resist various solvents, and 
are optically transparent.31 An optically transparent chip would allow for inverted phase 
contrast microscopy of the culture and measurement at all times.32  
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Polymers or elastomers are the most popular material for microfluidic chip 
fabrications.31 The advantages of elastomers include low cost, rapid and simple 
prototyping, and properties that allow for complicated and parallel fluidic microfabrication 
in channel structures and cultures.31 The cross-linked polymers chains stretch and compress 
with external forces, which will allow these OoC models to more accurately prototype 
external forces on the system.31 Polydimethylsiloxane (PDMS) is commonly integrated 
into the fabrication of microfluidic devices. Due to its low surface tension, researchers can 
easily peel templates from a mold and seal them to other pieces of PDMS, glass, and 
substrates.31 The gas permeability of PDMS allows the surface of the device to be 
compatible for cell cultures in OoC models.31 Although PDMS seems to be the ideal 
material for microfluidics, researchers must take into account that PDMS is insoluble with 
organic solvents, thus restricting it to aqueous solutions.31 In addition, quantitative 
experiments using PDMS are not as reliable since researchers have found that it absorbs 
small hydrophobic molecules and biomolecules, such as carbohydrates.29 
Yet another option is hybrid and composite material, which combine at least two of 
the common materials. PDMS and glass are typically used for research labs while plastic 
is used for commercial devices.31 The combination of PDMS with other materials has 
proven successful in gut-on-a-chip models in laboratories at the University of Maryland.33 
Current gut-on-a-chip models are fabricated via soft lithography, which shapes PDMS on 




2.2.2 Biofabrication & Soft Lithography 
 Biofabrication has recently been introduced as a way to construct imitations of 
biological products in fluidic systems with minimal instrumentation.33 It utilizes additive 
manufacturing, also known as 3D printing, for tissue engineering from cells, gels, and other 
biomaterials.34 Photolithography is the most dominant and powerful technique used in 
microfabrication, a subset of biofabrication. It is a parallel process and allows for the 
production of patterned structures in thin films of photoresists with features as small as 
approximately 250 nm. Although photolithography can also be used for creating larger μm-
scale features, it is not cost effective, allows no control of the chemistry of the surface, and 
is limited to use with a small set of photosensitive materials.35  
An extension to photolithography is soft lithography, which uses replica molding 
of nontraditional elastomeric materials to fabricate PDMS blocks or stamps and 
microfluidic channels.36 An elastomeric block, commonly PDMS or, in some cases, 
silicone rubbers, with patterned relief structures on its surface is the main element of soft 
lithography. A prepolymer of the elastomer is poured over a master having the relief 
structure on its surface, which is then cured and peeled off.35 Once cured PDMS is 
delaminated from the mold, which can then be bonded to glass slides by oxygen plasma 
treatment.31 
 Soft lithography offers many advantages in producing a variety of functional 
components and devices. It can be utilized in areas ranging from optics to microanalysis to 
display to microelectromechanical systems (MEMS), to microelectronics. It serves as an 
optimal fabrication method for constructing a microfluidic device such as the gut-on-a-chip 
model. Soft lithography also allows for fabrication of complex, optically-functional 
surfaces, and functional microelectronic devices in order to accommodate circuitry.32 This 
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technique is the prominent fabrication method for OoC models because it illustrates the 
advantage of flexibility in terms of extending micropatterning into dimensions, materials, 
and geometries.32  
2.2.3 Fabrication of Internal Microenvironment   
 The microenvironment of the gut-on-a-chip model will consist of two components: 
human cells and bacteria that make up the microbiome of the intestines. Caco-2 cells are a 
continuous cell line of heterogeneous human epithelial colorectal adenocarcinoma cells 
derived from the colon carcinoma.37 They can be differentiated and polarized to be 
phenotypically, morphologically, and functionally similar to enterocytes.37 Additionally, 
Caco-2 cells can undertake transepithelial ionic transport and can express small intestine 
microvilli hydrolases and nutrients transporters, microvilli and tight junctions.37  
2.2.4 Three-Dimensional Printing 
 Three-dimensional (3D) printing, also known as additive manufacturing, is a recent 
and growing interest in the realm of microfluidic devices. Traditional lithography requires 
extensive external equipment to regulate the internal functions of the microfluidic chips. 
To address this limitation, 3D printing shows potential in printing microfluidic circuitry. 
The general approach to fabricate 3D structures includes extrusion-based deposition, 
stereolithography (SLA), and multijet modeling (MJM).38 The extrusion-based or nozzle-
based techniques are usually used to create sub-millimeter scale cellular constructs and are 
primary methods of 3D printing.38 SLA has been used to fabricate resistor link components 
that are useful in microdroplet generation and even cell culture at the hundreds of microns 
resolution. SLA can only support one material being printed, thus limiting the use of 
sacrificial material for supports in complex structures.38 MJM, however, allow for tens of 
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microns resolution and the printing of numerous materials simultaneously.34 This is a 
valued aspect of MJM, and in recent years, has been examined from the static and dynamic 




2.3.1 Potential Sensor Options 
A primary focus of this research will be different types of sensors and how they can 
be manipulated to sense biological molecules. Biochemical properties such as temperature, 
pH, and oxygen levels can be measured using two types of sensors. Amperometric oxygen 
sensors can detect oxygen concentrations as the surrounding electrical current changes. 
There are also chemo-sensors, which can measure ion concentrations such as potassium, 
sodium and chloride.40 Two types of chemo-sensors, ion-sensitive field-effect transistor 
(ISFET) sensors and chemical field-effective transistor (CHEMFET) sensors, have many 
different applications in medicine and biomedical research. Some of the many applications 
include a penicillin sensor, urea detector and glucose sensor. ISFET sensitivity is 
dependent on the gate dielectric material, which usually consists of silicon and metal oxides 
or nitrides. While ISFETs can only detect hydrogen ions, CHEMFETs possess the 
technology to detect other ions.41 These sensors provide perfunctory quantitative 
measurements, but pH and temperature will be held constant in the gut-on-a-chip model in 
order to reduce confounding variables, rendering these sensors nonessential.  
Nanostructured microelectrodes (NMEs) have been used in the past for the sensitive 
detection of nucleic acids, proteins, and small molecules. Their high sensitivity makes them 
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ideal for applications in which small sample volumes are desirable.42 However, NMEs that 
detect small molecules relevant to C. difficile or vancomycin do not exist. To create an 
entirely new class of sensors would not be feasible with the limited amount of time and 
resources available. 
Yet another type of sensor that can be used is a magnetic cell-based sensor. 
Conventional sensors generally use chemical, optical, spectroscopic, electrical impedance- 
or mass-based detection to interpret biochemical phenomena. Cell-based sensing makes 
use of living cells or tissues as an integral part of the sensor and utilizes inherent cellular 
mechanisms to perform accurate detection of cell- or tissue-specific responses. This type 
of sensor can provide high sensitivity and specificity. Depending on the application of 
interest, the magnetic cell-based sensor can be outfitted with a variety of cell types with 
diverse functionalities. Such a sensor can be used to detect any range of biochemical 
agents.43 Despite these advantages, this sensor is not easily adaptable to different 
applications. For every target molecule, a new sensor would have to be created. Moreover, 
the fabrication of such sensors would be convoluted, as this technology is novel and not 
very well understood yet. This research requires established and reliable sensors to 
integrate in the model. Similar to the ISFETs and CHEMFETs, limited time and resources 
do not allow for this.  
2.3.2 Catechol-Chitosan Redox Sensor 
To assay biomolecules, one can typically use mass spectroscopy or 
chromatography or various “omics” methodologies. All of these methods require the 
researcher to take a sample, treat the sample, and subject it to a large, off-line, analytical 
method. On the other hand, biology offers the ability to detect biology. Enzymes can be 
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used to recognize and quantify the level of enzyme substrates. Enzymes, however, cannot 
be assembled into microfluidic devices during the construction of the device. Lithography 
and PDMS molding use high temperatures and toxic materials that do not allow for the 
incorporation of biological entities to be assembled within the devices. Further, biological 
entities that are incorporated into devices are stable for relatively short periods of time. 
Using a catechol-chitosan sensor offers a method to incorporate the enzyme into the device 
near where the measurement is needed and at a time near when the measurement is needed. 
Chitosan is ideal for its weak polyelectrolyte properties as it is deprotonated and soluble at 
low pHs and protonated and insoluble at high pHs.44 Its approximate pKa of 6.5 is in the 
ideal range for biological applications. Chitosan’s pH responsive film-forming properties 
allow it to yield 3-D hydrogel networks.45 To create the sensor, chitosan is electrodeposited 
onto a gold electrode, which would then be able to measure electric potentials caused by 
redox reactions.38 Gold is used in biomedical applications due to its biocompatibility. Other 
metals, like platinum and iridium are easily oxidized, while gold is much more stable. It is 
also a better conductor than aluminum, copper and silver.44 Anodic electrodeposition is 
used to create the film on the gold electrode. Particles (GOx) that are dissolved in a liquid 
medium (chitosan) migrate towards the metal using an electric field and are deposited in a 
stable film onto the electrode.46 The thickness of the film is dependent on the duration of 
deposition. Anodic deposition is chosen over cathodic because it allows for a more durable 
film. A film created by cathodic deposition would require layer-by-layer assembly in order 
to ensure imperishability. Anodic deposition allows for a one-step method for 
electrodepositing the chitosan solution.47  
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While this sensor can only detect for redox-active molecules, non-redox-active 
molecules can still be detected by reacting them with other redox-active molecules. For 
example, in order to detect glucose concentration, glucose oxidase (GOx) can be added to 
facilitate the reaction between glucose and oxygen, which forms gluconic acid and 
hydrogen peroxide (H2O2) while oxygen concentration is held constant as shown in 
Equation 2.1. The H2O2 will subsequently apply a current to the electrode as shown in 
Equation 2.2, which will allow for detection of the molecule. The concentration of H2O2 
will be used to extrapolate the unknown glucose concentration using Equation 2.1. 
C6H12O6  +  O2 C6H12O7 + H2O2  
Equation 2.1 In this equation glucose (C6H12O6) is reduced using oxygen (O2) to create gluconic 
acid (C6H12O7) and H2O2. 
 
H2O2 O2 + 2H+ + 2e-  
Equation 2.2 In this equation H2O2 is oxidized to create O2, protons (H
+), and electrons (e-).     
 
2.4 The Disease:  Clostridium difficile Infection 
2.4.1 Impact of Infection 
 
Figure 2.5 Clostridium difficile 48 
 
According to a study released by the Center for Disease Control and Prevention 
(CDC), every year, approximately half a million patients in the United States are infected 
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by a fatal, rod-shaped bacterium called Clostridium difficile (Figure 2.5).45 This bacterium 
causes the colon to be inflamed, which leads to extreme and, possibly, fatal diarrhea. C. 
difficile infection is a contagious disease that can be spread orally. It has been noted that 
29,000 patients die within one month of being diagnosed with the infection and, of those 
people, about 15,000 die as a direct result of CDI treatment.49 In fact, over the years, it has 
become the leading cause of microbial healthcare-associated infections in U.S hospitals. 
Currently, about 76 percent of CDI’s occur in hospital patients, a large proportion of which 
are diagnosed within two months of receiving antibiotics.50 Once contracted, the disease 
can be so severe, it often forces patients to extend their hospital stay by an average of 21 
days.51 
Moreover, people who are taking antibiotics are at the highest risk for developing 
CDI. When patients are prescribed several antibiotic treatments concurrently, beneficial 
bacteria in the gut can be suppressed or harmed. Without these benign bacteria in the body, 
the rapid growth of C. difficile can lead to serious consequences. The bacteria produce 
toxins that destroy cells in the lining of the intestine and produce plaques of inflammatory 
cells. Ultimately, the cellular debris inside the colon decays and causes watery diarrhea.49 
2.4.2 Potential Treatment Methods 
One of the most common treatments for CDI is vancomycin, which attacks the most 
severe forms of the disease. Other, more novel treatments, such as fecal microbiota 
transplantation (FMT), are now being studied as well. Microbiota transplantation involves 
eradicating the bacteria from an infected gut and replacing it with a whole new microbiota 
via fecal transplant or a fecal matter pill. The FDA has recently classified FMT as an 
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investigational new drug for treating C. difficile infection which is unresponsive to standard 
therapies, which signals a promising future for FMT treatment.52,53 
Initial treatment for CDI involves discontinuing the use of offending 
antimicrobials. Historically this was able to resolve symptoms for 20 to 25 percent of 
patients within 48 to 72 hours.49 However, due to the evolution of more pernicious strains, 
delaying the administration of specific therapeutic measures is not advised. The most 
common treatments for CDI are vancomycin and metronidazole. These antibiotics need to 
be introduced into the colonic lumen where the C. difficile is located, and toxins that result 
in colitis symptoms are produced.54 Between 1977 and 1980, most physicians prescribed 
oral vancomycin to treat confirmed cases of CDI. In the early 1980s, metronidazole was 
found to be just as effective as vancomycin.55 
Oral vancomycin serves as the prime antibiotic in CDI treatment. As low levels of 
the drug are absorbed, there are virtually no serum levels, and colonic levels are very high.54 
Vancomycin was first sold in the 1950’s and later approved officially for use by the U.S. 
Food and Drug Administration (FDA). This resulted in vancomycin becoming the standard 
treatment for colitis. In the past 20 years, alternative treatments for CDI such as bacitracin, 
fusidic acid, and teicoplanin have emerged; however, vancomycin and metronidazole have 
surfaced as top candidates for treatment as selected by clinicians of the field.54 Given 
metronidazole’s high absorptivity in the small bowel, vancomycin has since been 




2.5 Treatment of Interest 
2.5.1 Vancomycin 
 
Figure 2.6 Front and back images of 250 mg tablets of vancomycin 56 
 
Vancomycin (Figure 2.6) is a glycopeptide antibiotic synthesized by the 
Amycolatopsis genus. It consists of the sugar vancosamine, two β-hydroxycholortyrosine 
units, and three oxygenated phenylglycine systems.57 Vancomycin works by inhibiting the 
bacterial synthesis of peptidoglycan in the following manner. 
The bacterial cell walls of C. difficile consists of peptidoglycan, which is composed 
of two polymers: N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG).57 In the 
absence of vancomycin, peptide chains are able to form hydrogen bonds with the NAM 
and NAG backbone, and the enzyme transpeptidase is able to cross-link the peptide chains, 
allowing for the synthesis of peptidoglycan. The site of this bond is the d-alanyl d-alanine 
residue at the end of the peptide chain. When vancomycin is introduced, it binds to that d-
alanyl d-alanine residue, preventing transpeptidase from completing the cross-linkage, and 
peptidoglycan subsequently does not form, causing the cell wall to disintegrate.58 
2.5.2 Advantages and Disadvantages of Vancomycin 
According to Bartlett, metronidazole has sometimes been favored, due to its low 
cost, lower disposition for abuse, and possible decrease in likelihood for vancomycin-
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resistant enterococci.59 On the contrary, vancomycin has numerous advantages including 
its long history of use, key pharmacological characteristics (especially for an intra-lumenal 
pathogen), and lack of apparent, adverse side effects. Through in vitro clinical trials of both 
drugs, results have indicated a consistent activity against CDI, and, in both cases, there has 
been no convincing evidence of drug resistance. Rate of relapse for both drugs is estimated 
to occur in about 15 to 25 percent of cases.54 
It is believed that the distinguishing factor between the effectiveness of the two 
drugs is the degree of absorptivity along the path to the target area of the colon. Since 
metronidazole is completely absorbed in the small bowel, low levels of the antibiotic to 
reach the colonic lumen, which ultimately fails to prevent the production of colitis-causing 
toxins. Conversely, vancomycin is better able to resist absorption along its path to the 
colon, thus allowing for higher concentrations of the drug to reach its target area and 
effectively prevent the production of colitis-causing toxins.43 A recent study conducted by 
the University of Illinois at Chicago further provides supporting evidence that vancomycin 
is a more effective treatment than metronidazole in those patients who are judged to have 
a severe form of the disease. Results of the study show clear superiority for vancomycin in 
terms of cure rates for those with severe symptoms (76% vs. 97%; P=.02).60 Metronidazole 
and vancomycin have similar risks of recurrence, but vancomycin has resulted in fewer 
deaths.61 The conclusion of this study ultimately indicated that vancomycin is the preferred 
drug for the treatment of seriously ill CDI patients since it comparatively maintains 
superior efficacy over other treatment options.57 Furthermore, a 2017 study confirmed this 
fact, demonstrating a statistically significant reduction in all-cause 30-day mortality from 
severe CDI treated with vancomycin compared to metronidazole. Therefore, it can be 
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concluded that, while metronidazole may be effective in treating mild to moderate cases, 
vancomycin should be reserved for more effective treatment of severe cases of infection.48 
2.5.3 Recolonization after Antibiotic Treatment 
A major precursor for C. difficile infection is the use of antibiotics. After a course 
of antibiotics, the normal gut flora will be depleted, and there is a chance that the 
microbiome of the GI tract will be recolonized by different bacteria than those that existed 
previously. Another study found that after broad spectrum antibiotic treatment, bacteria 
from the phylum Verrucomicrobia, specifically A. muciniphila, recolonized the digestive 
tract at a concentration of over 40 percent.62 Concentrations this high had never been 
previously reported, and earlier analysis showed that A. muciniphila constituted no more 
than 1% of fecal cells.63 Recently, FMT has emerged as a potential treatment for C. difficile. 
In a fecal transplant, the feces of healthy individual is administered via nasogastric and 
nasoduodenal tubes, a colonoscope, or as a retention enema.64 This reintroduces the normal 
flora to the gut, allowing normal bowel function to resume.65 Although the procedure has 
seen limited use, the published results from 100 patients treated with FMT show a 90% 
cure rate.65 This process of recolonization will be analyzed with a drug whose usefulness 
is well known first in order to assess the efficacy of the gut-on-a-chip model, and later 






Chapter 3: Methodology 
3.1 Objectives 
This chapter will focus on the fabrication of the gut-on-a-chip device, in addition 
to the fabrication, integration and calibration of the glucose sensor that is integrated into 
the model. The gut-on-a-chip is a two-channel microfluidic device, which is created using 
soft lithography. This is the ideal method due to its flexible applicability to different 
materials and ability to facilitate the modeling of the surface chemistry of the gut. The 
sensor design incorporates a catechol chitosan redox capacitor and gold electrode, and 
enables monitoring of glucose concentration changes in the presence of bacteria and/or 
antibiotic. It is shown that the sensors developed have potential to accurately model the 
biochemical changes in the gut during infection and drug administration. As noted above, 
the methodology we have developed for the incorporation of an enzyme-based redox 
biosensor is completely new. It takes advantage of the unique pH-dependent solubility of 
chitosan and the redox-actuated ability to covalently incorporate glucose oxidase. 
 
3.2 The Gut-On-A-Chip  
3.2.1 Chip Component Design 
Two gut-on-a-chip models are designed. The first design is an “X” shape that has a 
0.2 mm wide central channel and 1 mm wide arms (Figure 4.1A). The overall dimensions 
of this chip are 8 mm by 5.5 mm. This design is created with the intention of 3D printing 
of microvilli within the central channel. Conversely, the second design integrates the pores 
into the structure of the chip. This version of the chip optimizes the increased surface area 
for cell growth and proliferation. The dimensions of the chip are approximately 16 mm by 
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9.15 mm with the outer two channels being 2.3 mm in thickness and the central channel 
being 3.5 mm in thickness (Scheme 3.1B). The pillars between the channels have a 
diameter of 0.01 mm and are 0.02 mm apart (Scheme 3.1C). 
Prior to chip fabrication, the designs are drawn on Autodesk Inventor and viewed 
in autoCAD, which are both computer aided design softwares. This designs are printed on 
plastic film by CAD/Art Services, Inc. 
 
Scheme 3.1 (A) The photomask designed using AutoCAD software depicting the multiple chip 
copies per silicon wafer (B) The 3-section chip designed using AutoCAD software. (C) AutoCAD 
design of the pillars aligned between the channels. 
 
 The design for the gold electrode stencil (Scheme 3.2) is also drawn on Autodesk 
Inventor. The three-electrode system consists of the outer counter electrode, the square 
shaped working electrode and the small reference electrode. The design is spaced so that 
the electrode is centered at the ends of the outer channels. This 302/304 stainless steel full 




Scheme 3.2 (A) The design of the gold electrode stencil (B) One of the gold electrode designs, 30 
mm in diameter, with four three-electrode systems. (C) Three-electrode system design 
The three separate sections shown in Scheme 3.1B fit cells in the center section and 
the 3-electrode sensor system in the outer sections. A line of pillars, signified by the dots 
between channels in Scheme 3.1C, allow for the flow of media over the electrodes whilst 
keeping the Caco-2 cells confined to the center compartment so as not to interfere with the 
sensor function. The masks obtained from CAD/Art Services Inc. and Thin Metal Parts are 
used to create a silicon wafer, which is then used to create the final PDMS chip with gold 
electrodes, as explained in Sections 3.2.2 and 3.2.3.  
3.2.2 Fabrication of the Chip  
The mask shown in Scheme 3.1 is used to create an SU-8 photoresist mold using 
standard soft lithography methods. A 4-in. silicon wafer is sterilized with acetone, 
isopropanol (IPA), and distilled water before 5 mL of SU-8 2050 photoresist (MicroChem, 
Westborough, MA) is deposited on the wafer, which is then spun at 2600 rpm for 30 
seconds and baked in a pre-exposure phase at 95℃ for 15 minutes. The design is imprinted 
onto the SU-8 mold through UV light exposure (405 nm wavelength) at 23.4 mW∙cm-2 
using an EVG 620 mask aligner (Electronic Visions Inc., Phoenix, AZ). The wafer 
undergoes a post-exposure baking phase at 95℃ for another 15 minutes before being 
agitated in a solution of SU-8 developer (MicroChem, Westborough, MA) for 10 minutes. 
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Residual SU-8 is rinsed away by isopropanol and deionized (DI) water. The final SU-8 
mold is then left to air-dry and can be reused. 
An elastomeric block of polydimethylsiloxane (PDMS) (Sylgard 184, Dow 
Corning Co., Midland, MI) is fashioned using the SU-8 photoresist mold. The PDMS and 
curing agent is mixed at a ratio of 10:1, respectively, and baked at 65°C for approximately 
1 hour. Once solidified, the PDMS is delaminated from the mold. Finally, a 1.0 mm Harris 
Uni-CoreTM (Ted Pella, Inc., Redding, CA) biopsy punch is used to punch inlet and outlet 
holes in the PDMS design. In order to complete the gut-on-a-chip model, this PDMS base 
must be plasma bonded to a glass coverslip containing the gold electrode sensor with the 
appropriate design.  
3.2.3 Fabrication of the Gold Electrode 
To create the gold electrode pattern on the glass cover slide, the cover slide is 
carefully aligned and attached to the mask. The chamber of the METRA Vacuum 
Equipment Machine is isolated by turning off the gauge and closing the gate valve, and 
filled with nitrogen through the rotation of the turbo molecular pump. The gold boat and 
chrome rod are clamped into the electrodes, before the mask can be secured into place 
above the shutter. The air is pulled out of the chamber to decrease the pressure reading to 
150 mTorr. The ionization gauge is then turned on to form the current on the rear electrode 
before the control setting is switched back to the front electrode. The density for the chrome 
is set to 7.200 g∙cm-3 with a Z-ratio of 0.305. 100 A of current are outputted to lower the 
pressure, after which the output control is gradually increased from 1 A∙s-1 to 50 A∙s-1 to 
deposit the chrome adhesive layer. Before depositing the gold, the shutter and power supply 
are turned off to again increase the pressure. From the rear electrode, the output control is 
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slightly increased and the density is changed to 19.3 g∙cm-3, with a Z-ratio of 0.381 for the 
gold deposition. When the rate of deposition reaches its maximum and the thickness of the 
gold reaches approximately 1 mm, all power supply and valves are turned off before 
removing the mask from the chamber. The gold deposited cover slides are then ready for 
oxygen plasma treatment (IPC 4000 series plasma system) (Branson, PA). The PDMS chip 
and gold electrode cover slide are aligned appropriately and plasma bonded to form a single 
microfluidic device. 
3.2.4 Three-Dimensional Printing Microvilli 
Using Autodesk Inventor CAD software, a single microvillus with the following 
dimensions is tailored: 0.2 mm wide and 1 mm long. The vertical pores at the base and 
circular pores at the tip are 10 μm in diameter (Scheme 3.3). These characteristics mimic 
the finger-like shape and projection of intestinal microvilli. This design is uploaded to the 
DeScribe software, which is compatible with the NanoScribe Photonic Professional GT 3D 
printer (Nanoscribe, Eggenstein).  
A top-down printing method, adapted from the methodology of Bioengineering 
PhD candidate, Wu Shang, is used to 3D print porous microvilli directly into the sol gel-
coated central channel of the “X” shaped chip. Using the DeScribe software, the initial 
laser power is set to 80%, and decreased by increasing increments with each layer to 
prevent the possibility of burning.  
To prepare the substrate for printing, a circular glass coverslip is first washed with 
acetone, IPA, and water, and dried completely. The coverslip is then secured in a perforated 
holder. A drop of oil is placed on the back side of the coverslip and OrmoComp is placed 
on the front side for printing. The entire holder is then placed under the 63X objective lens 
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of the printer, and the “inverted z-axis” setting is selected to print using a top-down 
approach. The completed print can then be imaged using a microscope.  
 
 
Scheme 3.3 CAD drawing of porous microvilli 
3.3 Cell Studies 
3.3.1 Preliminary Caco-2 Cell Culture 
Human intestinal epithelial Caco-2 cells (Caco-2 BBE human colorectal carcinoma 
cells) are grown in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Grand Island, 
NY) containing 4.5 g∙L-1 glucose, 100 units∙mL-1 penicillin, and 100 mg∙mL-1 
streptomycin (Gibco), 25 mM HEPES supplemented with 10% fetal bovine serum (FBS). 
These cells are maintained at 37℃ in a humidified incubator under 5% CO2. Cells are 
maintained according to ATCC standards.63 The cells are grown to 75% confluency before 
seeding inside the device.  
3.3.2 Implantation of Caco-2 cells into gut-on-a-chip model 
The microfluidic device is first sterilized by injecting 70% (v/v) ethanol into the 
microchannels and dried in a oven heated to 65℃ for 10 minutes. Then, the device is 
exposed to UV light for 40 minutes. The channels are coated with type I collagen and 
matrigel mixture for the next 2 hours. Caco-2 cells are inserted into the device at a 
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confluency of 1.5 x 105 cells∙cm-2 and allowed to settle for 1 hour. DMEM is continuously 
flowed at a rate of 30 µL∙h-1 using a GenieTM Plus Syringe Pump (Kent Scientific, 
Torrington, CT) and replenished when needed.  
 
3.4. The Sensors 
3.4.1 Electrodeposition Solution Preparation  
In this phase, a chitosan solution with GOx is created for subsequent 
electrodeposition. First, a 1% (w/w) chitosan solution is prepared by dissolving chitosan 
flakes in an acidic solution.47 The acidic solution consists of acetic acid (HAc) and 
deionized water. After two hours, if the pH is between 5 and 6, but the chitosan flakes are 
not dissolved, HAc is added dropwise until the chitosan is fully dissolved. If the pH is 
below 4, more chitosan flakes are added. The solution is finally filtered to remove any 
remaining undissolved particles.  
Next, the anodic electrodeposition solution is created by adding GOx and sodium 
chloride (NaCl) to the previously prepared chitosan. The previously made chitosan solution 
is combined with GOx (680 U·mL-1) and NaCl (0.15 M).47 
3.4.2 Electrodeposition 
This phase focuses on glucose sensor fabrication. First, a preliminary sensor is 
created on an external gold electrode in order to perfect protocol design and testing 
methods. The base of the sensor is a two-dimensional silicon wafer, on which a layer of 
gold is deposited. The circular wafer is cut into rectangular pieces, where each piece will 
become a single sensor.  
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Next, a gold electrode and counter electrode are immersed in the electrodeposition 
solution. The electrodes are connected to a potentiostat. For anodic deposition, the anode 
is the working electrode and the cathode is the counter electrode.47 A current density of 4 
A·m-2 is applied for 105 seconds.  After electrodeposition, the electrode is rinsed carefully 
with water. 
 
Scheme 3.4 Electrodeposition set-up on external electrode 
 
The electrodeposition methodology is then adapted to create a sensor for use in the 
microfluidic device. Gold is deposited on a glass cover slide and plasma bonded with the 
microfluidic device to create the gold electrode (Section 3.2.3). A three-electrode system 
is utilized for electrodeposition and testing (Scheme 3.5). Using a syringe, the channel is 
completely filled with the electrodeposition solution. The counter and working electrodes 
are connected to the potentiostat and a current density of 4 A·m-2 is applied for 105 seconds. 
After electrodeposition, a 0.15 M phosphate buffer solution is flowed through the channel 




Scheme 3.5 The 3-electrode system utilized for deposition and testing of the glucose 
sensor. Deposition requires a counter and working electrode. Sensor testing requires the 
additional reference electrode. There are four electrode systems spaced throughout the device.  
 
3.4.3 Sensor Testing 
20% glucose is mixed with 0.15 M phosphate buffer to create the following 
concentration solutions: 2 mM, 4 mM, and 6 mM. In order to test the preliminary sensor, 
the working, counter, and reference electrodes are connected to the CHI6273C 
Electrochemical Analyzer (CH. Instruments, Inc., Austin, TX). The electrodes are 
submerged in the different concentrations of glucose solution sequentially and a constant 
voltage of 0.6 V is applied. The resulting current is measured and graphs for each glucose 
concentrations are obtained. The same process is used to test the integrated sensor; 
however, the glucose solutions are flowed through the channel instead of submerging the 









Chapter 4: Results 
4.1 Creation of the Gut Microenvironment  
It was hypothesized that creating a PDMS gut-on-a-chip model with 3D printed 
microvilli structures will mimic the absorption and passage of nutrients and wastes from 
the human gut epithelial cells to the surrounding environment. The initial gut-on-a-chip 
design was fabricated with an “X” shaped design where Caco-2 cells were concentrated in 
the center and the media was contained at the ends of the design (Figure 4.1A). This design 
was optimal for microvilli incorporation in the center of the “X.” A single microvillus 
structure, 200𝜇m high and 60𝜇m wide, was 3D printed using the Nanoscribe printer and 
visualized using confocal microscopy (Figure 4.1B and C). The lack of contrast in Figure 
4.1B indicates an unstable print, and the wavy demarcations between the vertical and 
circular pores of the villus in Figure 4.1C demonstrate low resolution.  
 
Figure 4.1 (A) Initial design of the PDMS gut-on-a-chip design in an “X” design. The width of 
the central channel is 0.2 mm wide. (B) 40X image of print with minimal spotted burning and (C) 
20X confocal microscopy images of 3D printed porous microvilli outside of the gut-on-a-chip, 
using the NanoScribe 3D printer.  
 
Due to limitations in the 3D printer, an alternative design that replaced the need for 
microvilli was fashioned and tested. It was hypothesized that an alternative design of the 
gut-on-a-chip model with a larger middle channel separated by PDMS pillars to prevent 
the infiltration of the cells into the other channels and still allow for the diffusion of 
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nutrients and wastes would be superior. The larger middle channel held Caco-2 cells, and 
the two outer channels contained media to provide nutrients to, collect waste from, and 
maintain viability of the Caco-2 cells. To test this hypothesis, the cells seeded inside the 
PDMS gut-on-a-chip model were imaged using confocal microscopy immediately after 
seeding and after 1 day of incubation (Fig. 4.2A and B). The cells increased in both number 
and size 24 hours after seeding within the chip, forming a monolayer. 
 
Figure 4.2 (A) Cells seeded in the chip and aggregated around the PDMS pillars at 0H.  
(B) Cells, viewed at 10X under confocal microscopy, adhered to the chip at 24H post-seeding. 
4.2 Integration of Gold Electrode Sensors 
 
Figure 4.3 The final PDMS gut-on-a-chip model plasma bonded to the glass slide with gold 
electrodes. The blue arrow indicates one of the ten contact electrodes around the chip for easy 
access to connect to a current source. The red arrow indicates one of the four sensor systems on 
the outer channels of the chip. The purple arrow indicates one of six total inlet holes.  
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It was hypothesized that the inclusion of glucose oxidase in the catechol-chitosan 
redox sensor would allow for the measurement of the glucose concentration in a sample.47 
The glucose sensor was created on one of the three-electrode systems in the model as 
shown in Figure 4.3. Amperometric I-t experiments to test sensor functionality were 
conducted using glucose concentrations of 2 mM, 4 mM, and 6 mM. When glucose 
solutions were added to the chip model, an immediate current response was induced as 
shown in Figure 4.4. The current response was linearly proportional to the concentration 
of glucose in the solution; larger concentrations of glucose resulted in a larger current. 
Using the current responses for sequential concentrations, a standard curve was created by 
plotting current versus glucose concentration. As shown in Figure 4.5, an R2 value of 
0.9223 was obtained for one such sensor. 
 
Figure 4.4 Current response of glucose sensor upon addition of 2 mM (A), 4 mM (B), and 6 mM 
(C) glucose solutions. The sharp decline in current indicates the addition of the glucose solution. 





Figure 4.5 Standard curve of current versus glucose concentration created using sensor output 




Chapter 5: Discussion 
 
These findings suggest that (i) PDMS gut-on-a-chip models can mimic the human 
gut’s ability to passage nutrients and wastes from Caco-2 cells to the environment, and (ii) 
gold electrode sensors deposited in the model are able to detect glucose.  
5.1 3D Printing of the Microvilli Structures 
The gut-on-a-chip model can serve as an alternative in vitro model to mimic the 
human gut and test novel drug treatments. One of the original objectives of this research 
was to improve the structural accuracy of the existing gut-on-a-chip model. In order to 
achieve this, microvilli structures were created to increase absorption. In this study, these 
microvilli structures were 3D printed into the gut-on-a-chip model (Figure 4.1) with an 
initial prototype design. Initial 3D printing attempts resulted in burning, which, due to the 
high laser power, was inferred. The laser power was experimentally reduced in various 
increments to determine the optimal settings that would produce a stable print implanted 
in the substrate without burning. However, it was discovered that the degree of burning 
was arbitrary and the most favorable laser power for each layer of the print could not be 
determined.  
The least amount of burning was seen in the print where the initial laser power was 
set to below 80% and decreased incrementally with each layer (Figure 4.1B). 
Unfortunately, decreased laser power seemed to excessively compromise the stability of 
the microvillus in the substrate (Figure 4.1C). Two factors may have contributed to this 
“floating” print. First, a tiny crack in the coverslip, which seemed to be out of the vicinity 
of the print, may have increased under the laser beam. Second, even with an intact 
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coverslip, overall inconsistency and lack of correlation between laser power adjustment 
and amount of burning suggests a possible limitation of the 3D printer.  
Burning seemed to occur most frequently at the interface of the vertically porous 
and circularly porous parts of the villus, which indicates that the printer may be unable to 
effectively resolve the sudden structural change. This discovery warrants a project of its 
own dedicated to testing different iterations of a porous design, ranging from a simple block 
to structures closely resembling actual microvilli. Because 3D printing of microvilli was 
deemed overly ambitious and infeasible within the available time constraints, a new chip 
design with an integrated filtration system was developed. To further improve the accuracy 
of the gut-on-a-chip model, future research may be focused on refining 3D printing to 
successfully incorporate porous microvilli. To increase the superiority of this gut-on-a-chip 
model, a new design was proposed.  
 
5.2 Biofabrication of an alternative PDMS gut-on-a-chip model  
This PDMS chip served its purpose as a biocompatible device in which to seed 
cells, as shown in Figure 4.2. The current 3-channel design would enable maximum cell 
seeding and optimal sensor readings since cells are restricted to the middle channel, while 
fluid flow throughout all three channels allows for data collection by sensors. Although the 
pillars did not successfully keep all of the cells out of the two outer channels during initial 
seeding (Figure 4.2A), they prevented excessive migration and growth on the sensors. 
During the seeding period, cell viability was monitored by qualitatively analyzing cell 
confluency and size. Due to the microscopic surface area for cells to grow in, the cells were 
observed after a period of only one day to determine cell viability. The formation of 
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monolayer after cell seeding is a good indication that the cells had adapted to the growth 
conditions in the chip and begun to mimic the endothelial cell growth formations in the 
gut. However, medium evaporation depleted the cells of nutrients to maintain viability 
within the device. 
Medium evaporation became an unexpected challenge with cell culture in which 
there are several plausible explanations for this phenomenon. There may be too many inlets 
and outlets, allowing for culture medium to easily escape the device. The humidity of the 
device also may not have been properly maintained, causing the device to dehydrate. 
Additional experiments and trials are needed to eliminate this issue. Humidity can be 
restored and maintained by saturating the local environment with distilled water or PBS 
solution. Furthermore, future device designs may also limit the number of inlets and outlets 
or adequate inlet and outlet plugs can reduce evaporation. 
5.3 Integration of gold electrode sensors  
 Functional catechol-chitosan redox sensors with glucose oxidase can be created 
within the gut-on-a-chip model to measure glucose concentration levels in a sample. The 
graphs depicting the current response (Figure 4.4) have some noise before and after the 
addition of glucose that is caused by the movement of the stir bar in the beaker. 
Nonetheless, stirring was crucial to ensure that the glucose was evenly distributed 
throughout the water. Despite the noise, the sensor output of known glucose concentrations 
led to the creation of a standard curve for the sensor. This standard curve can be used to 
extrapolate glucose concentrations from unknown samples. Specific to this device, cell 
metabolism can be quantified. When exposed to a disease, quantifiable changes in cell 
metabolism can signify the effects of the disease on the intestinal microenvironment. 
44 
 
Consequently, potential novel treatments can be tested and effects can be quantified with 
the sensors to measure effectiveness.  
 The creation of the glucose sensor on external gold electrodes served as a proof-of-
concept for the use of anodically-deposited catechol-chitosan redox sensors. Further testing 
must be conducted with the sensor deposited onto the gold electrodes within the chip model 
to ensure that the sensor fabrication methodology is effective. In the future, this sensor 
technology can be expanded to create a diverse range of sensors so long as a redox 





Chapter 6: Conclusion 
This research demonstrated the ability to improve existing microfluidic models of 
the GI tract through the assembly and electrodeposition of a glucose sensor into a gut-on-
a-chip device. Results from sensor testing showed that glucose concentration can be 
monitored at specific sites in the microfluidic device in real-time. Furthermore, preliminary 
cell studies indicated that cells could be seeded into a gut-on-a-chip device, and identified 
medium evaporation as a challenge to cell proliferation and viability for future works. 
Attempts at 3D-printing microvilli into the initial gut-on-a-chip design revealed challenges 
associated with directly printing into a PDMS base, such as arbitrary burning. Overall, 
these results provide a foundation for future research involving improving the accuracy of 
the gut-on-a-chip model by showing the feasibility of monitoring changing environmental 
conditions in the GI tract in vivo during pharmaceutical testing.  
In terms The original intention of utilizing the OoC device for the purpose of testing 
vancomycin on C. difficile remains of high priority. The vast array of research supporting 
the effectiveness of vancomycin in the treatment of C. difficile suggests that this long-
standing disease and treatment model would lend great support in testing the OoC and 
illustrating the effectiveness of the device by providing a platform to obtain more detailed 
and comprehensive data at a level previously unavailable.  
The ultimate ambition of this research remains to expedite drug testing and make 
the process more efficient and effective than the current FDA standard review process. This 
device has the potential beacon to eliminate human and animal testing by supporting and 
upholding drug evaluation to a superior standard than that which currently exists. The 
incorporation of sensors in the OoC device can increase functionality of not only gut on a 
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chip models, but in all available types of OoC’s. Structural improvements, combined with 
successful integration of sensors, creates the potential for a more efficient and perhaps a 
faster drug screening process, which will ultimately benefit pharmaceutical and biomedical 
research companies as well as the general public. It is in the best interest of these 
stakeholders that research on OoC models continues to progress so that the research 
community may continue to combat current limitations in traditional drug testing and 
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